Trial Profile
A Phase I/IIa Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) in Second Complete Remission (CR2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 26 Feb 2020 According to a Sellas Life Sciences Group media release, Javier Pinilla-Ibarz, MD, PhD, (Director of Immunotherapy for Malignant Hematology at the H. Lee Moffitt Cancer Center) is the principal investigator of this study.
- 26 Feb 2020 Final follow-up results presented in a Sellas Life Sciences Group media release.
- 14 Dec 2018 New trial record